Patent ID: 7462699

Claim:
A therapeutic immunoadsorption method of removing an anti-botulinum toxin antibody from an individual in need thereof, the method comprising the steps of: (a) removing blood from said individual; (b) contacting said blood, or an antibody-containing component thereof, with a BoNT/A peptide immunoreactive with an anti-botulinum toxin antibody under conditions suitable for forming an immunoreactive complex between said immunoreactive BoNT/A peptide and said anti-botulinum toxin antibody; wherein said immunoreactive BoNT/A peptide has a length of at most 60 amino acids, said BoNT/A peptide comprising amino acids 785-803 of SEQ ID NO: 1, a conservative BoNT/A amino acid sequence variant of amino acids 785-803 of SEQ ID NO: 1, or an immunoreactive BoNT/A amino acid sequence fragment of amino acids 785-803 of SEQ ID NO: 1; wherein said antibodies immunoreact with amino acids 785-803 of SEQ ID NO: 1, a conservative BoNT/A amino acid sequence variant of amino acids 785-803 of SEQ ID NO: 1, or an immunoreactive BoNT/A amino acid sequence fragment of amino acids 785-803 of SEQ ID NO: 1: wherein said conservative BoNT/A amino acid sequence variant immunoreactive with said anti-botulinum toxin antibody comprises 1-4 conservative amino acid substitutions to amino acids 785-803 of SEQ ID NO: 1; and wherein said immunoreactive BoNT/A amino acid sequence fragment immunoreactive with said anti-botulinum toxin antibody comprises at least six consecutive amino acids of 785-803 of SEQ ID NO: 1; (c) removing said complex from said blood, or antibody-containing component thereof, thereby forming anti-botulinum toxin antibody-depleted blood, or an anti-botulinum toxin antibody-depleted component thereof; and (d) returning said anti-botulinum toxin antibody-depleted blood, or said anti-botulinum toxin antibody-depleted component thereof, to said individual.